Search
Lactide, L-
go.drugbank.com/drugs/DB19115InvestigationalLactide, L- is under investigation in clinical trial NCT05450471 (Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis).
Pegadricase
go.drugbank.com/drugs/DB15129InvestigationalPegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).
Asunercept
go.drugbank.com/drugs/DB15160InvestigationalAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
NSI-189
go.drugbank.com/drugs/DB16230InvestigationalNSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
HP-001
go.drugbank.com/drugs/DB33944ExperimentalHP-001 is a small molecule drug. HP-001 is under investigation in clinical trial NCT07811986 (HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease).
Olacaftor
go.drugbank.com/drugs/DB16262InvestigationalOlacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Pidacmeran
go.drugbank.com/drugs/DB16401InvestigationalPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Bicyclol
go.drugbank.com/drugs/DB16014InvestigationalBicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).
Carotegrast methyl
go.drugbank.com/drugs/DB16119InvestigationalCarotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).
Pepinemab
go.drugbank.com/drugs/DB15155InvestigationalPepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).